Day: November 4, 2024

Presented clinical data for multiple assets across modalities, including bispecific antibody candidate BNT327/PM8002 and mRNA cancer vaccine candidate BNT113 based on BioNTech’s FixVac platform Initiated two Phase 2 dose optimization trials with BNT327/PM8002 in small-cell lung cancer and in triple-negative breast cancer to inform planned pivotal Phase 3 trials Phase 2 clinical trial on track to evaluate mRNA-based individualized cancer vaccine candidate autogene cevumeran (BNT122/RO7198457) as an adjuvant treatment in patients with high-risk muscle-invasive urothelial cancer Successfully launched variant-adapted COVID-19 vaccines for the 2024/2025 vaccination season in multiple regions Reports third quarter 2024 revenues of €1.2 billion, net profit of €198.1 million and diluted earnings per share of €0.81 ($0.89)1 Ended the third quarter...

Fee-Related Earnings up 14% Year-Over-Year to $644 Million $135 Billion of Capital Raised Over LTM, Growing Fee-Bearing Capital 23% to $539 Billion Brookfield Takes Initial Steps to Enhance Shareholder Ownership and Index Inclusion NEW YORK, Nov. 04, 2024 (GLOBE NEWSWIRE) — Brookfield Asset Management Ltd. (NYSE: BAM, TSX: BAM) today announced financial results for the quarter ended September 30, 2024. Connor Teskey, President of Brookfield Asset Management, stated, “We delivered record results in the third quarter, driven by the substantial increase in fee-bearing capital due to strong fundraising, deployment and additional strategic partnerships over the past year. This resulted in 14% year-over-year growth in fee-related earnings, while fee-bearing capital increased by 23% to $539 billion.” He continued, “This past quarter,...

Net income increased 29% to $11.1 million or $0.30 per share, a 36% increase Adjusted net income increased 36% to $15.9 million or $0.44 per share, a 47% increase Home sales revenue increased 26.2% to $325.6 million New home deliveries increased 40% to 629 homes Net new home orders of 626 increased 28.8% Home sales gross margin of 17.1%, adjusted home sales gross margin of 22.8% Book value per share of $18.27 DALLAS, Nov. 04, 2024 (GLOBE NEWSWIRE) — Landsea Homes Corporation (Nasdaq: LSEA) (“Landsea Homes” or the “Company”) announced today financial results for the third quarter ended September 30, 2024. For the quarter, the Company reported pretax income of $14.9 million, and net income of $11.1 million, or $0.30 per share. Adjusted net income (a non-GAAP measure) was $15.9 million or $0.44 per share and adjusted gross margin...

Gran Tierra Announces its Sixth Consecutive Ecuador Oil Discovery from the Charapa-B7 Well and Has Achieved Cumulative Production of Over 1 Million Barrels of Oil in Ecuador Gran Tierra Achieved $1 Million in Net Income and Generated $60 Million in Funds Flow from Operations(2), an Increase of 31% from Prior Quarter Third Quarter 2024 Total Average WI Production of 32,764 BOPD Operating Netback of $101 Million and Adjusted EBITDA of $93 Million(1)(4) Exited the Quarter with $278 Million in Cash Entered into new credit facility for further liquidity which is currently undrawn CALGARY, Alberta, Nov. 04, 2024 (GLOBE NEWSWIRE) — Gran Tierra Energy Inc. (“Gran Tierra” or the “Company”) (NYSE American:GTE) (TSX:GTE) (LSE:GTE) announced the Company’s financial and operating results for the quarter ended September 30, 2024 (“the Quarter”). All...

PRINCETON, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) — Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the third quarter ending September 30, 2024. Third Quarter 2024 Highlights Third quarter revenues of $380.8 million decreased 0.4% on a reported basis and 8.6% on an organic basis compared to the prior year. Revenue decreased 10.3% on an organic basis excluding Boston. Third quarter GAAP earnings per diluted share of $(0.14), compared to $0.24 in the prior year; adjusted earnings per diluted share of $0.41, compared to $0.76 in the prior year. Shipping holds communicated during the second quarter earnings call are releasing in line with expectations. Integra Skin production is on pace to meet historical revenue run rates for the fourth quarter. Updating...